VCX2 and breast carcinoma: A similar pattern was seen with the hormone receptor positive breast cancer cells MCF7; guadecitabine increased the frequency of VCX2-positive cells (from 0 to 23%) and again this was potentiated by addition of valproic acid (42%) (Figure 5D).